
Patrick Malone
Physician-scientist turned venture investor; Partner at KdT Ventures, backing early-stage life science and biotech founders, and writer of the Decoding Bio newsletter.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
Sep 17, 2026
Live from DC: Is secrecy the solution?
10:41
10:53
11:02
D
10:36Drew ArmstrongHOST
Walk us through what saying as little as possible actually means in the context of a biotech.

Patrick MaloneGUEST
So five years ago, uh, when we say we led a seed round, uh, we would probably either announce that round with some, you know, maybe some specifics or kind of high level points of like what, what, you know, what disease area we're going after.

Patrick MaloneGUEST
We may wait until the series a to announce right before that really with the goal to drive, uh, both partnering interest, fundraising interest, you know, recruiting.

Patrick MaloneGUEST
I mean, now we basically try to fundraise through every possible gate without ever saying anything about what the company does.
13 MINS LATER